IL6 and colitis: When administered orally at the dose of 0.1, 1 and 10 mg/kg/day for 4 days, oleanolic acid dose-dependently attenuated development of TNBS colitis, as measured by assessing weight loss, diarrhea and macroscopic scores as well as expression of signature cytokines (Il-10, TNFα and IL-6) in the colons (Figure 6D–I; n = 5, P<0.05 versus TNBS alone).